{"classes":[{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"MAAA-1181a: Cycle 1: Pre-infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.9","value":"4.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"}],"units":"Participants"}],"title":"MAAA-1181a: Cycle 1: 15 minutes post-infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.1","value":"10.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"}],"units":"Participants"}],"title":"MAAA-1181a: Cycle 1: 5 hours post-infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.1","value":"0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"}],"units":"Participants"}],"title":"MAAA-1181a: Cycle 2: Pre-infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.5","value":"2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"}],"units":"Participants"}],"title":"MAAA-1181a: Cycle 2: 15 minutes post-infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.2","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"title":"MAAA-1181a: Cycle 4: Pre-infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.9","value":"1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"title":"MAAA-1181a: Cycle 4: 15 minutes post-infusion"}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"}],"units":"Participants"}],"description":"Serum samples were collected at specified timepoints to determine serum concentrations of MAAA-1181a.","dispersionType":"Standard Deviation","groups":[{"description":"Participants harboring tumors with specific HER2 activating mutations received T-DXd 5.4 mg/kg via IV infusion on Day 1 of each cycle (21 days), every 3 weeks until RECIST v1.1-defined PD, withdrawal of consent, or until any other of the discontinuation criteria was met.","id":"OG000","title":"T-DXd"}],"paramType":"MEAN","populationDescription":"The Pharmacokinetic (PK) Analysis set consisted of all participants who received at least 1 dose of study treatment and had at least 1 post-dose evaluable PK data point. The population was defined by the study pharmacokineticist and the statistician prior to any PK analyses being performed. Only those participants with data available are reported.","reportingStatus":"POSTED","timeFrame":"Pre-infusion and 15 minutes post-infusion in Cycles 1, 2 and 4 and 5 hours post-infusion in Cycle 1 (each cycle 21 days)","title":"Serum Concentrations of Deruxtecan (MAAA-1181a)","type":"SECONDARY","unitOfMeasure":"ng/mL"}